General
Preferred name
CASOPITANT
Synonyms
CASOPITANT MESYLATE ()
Casopitant (mesylate) ()
GW679769B ()
Zunrisa ()
Rezonic ()
GW-679769 ()
GW679769 ()
Casopitant mesilate ()
GW-679769B ()
P&D ID
PD049995
CAS
414910-27-3
414910-30-8
Tags
available
drug
drug candidate
Drug indication
Chemotherapy-induced nausea
Nausea
Drug Status
approved
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Casopitant is an investigational NK1 receptor antagonist. (GtoPdb)
DESCRIPTION Casopitant mesylate (GW679769B) is a potent, selective, brain permeable and orally active neurokinin 1 (NK1) receptor antagonist. Casopitant mesylate is a second in the class of antiemetics that acts to antagonise the emetogenic effect of Substance P (HY-P0201). Casopitant mesylate is also a substrate and a weak-to-moderate inhibitor of CYP3A4. Casopitant mesylate can be used for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV)[1][2].
DESCRIPTION Casopitant has anti-emetic and antinausea activities. Casopitant competitively binds to and blocks the activity of the NK1 receptor. (Enamine Bioactive Compounds)
DESCRIPTION Casopitant mesylate is the mesylate salt of a centrally-acting neurokinin 1 (NK1) receptor antagonist with antidepressant and antiemetic activities. Casopitant competitively binds to and blocks the activity of the NK1 receptor, thereby inhibiting NK1-receptor binding of the endogenous tachykinin neuropeptide substance P (SP), which may result in antiemetic effects. SP is found in neurons of vagal afferent fibers innervating the brain-stem nucleus tractus solitarii and the area postrema, which contains the chemoreceptor trigger zone (CTZ), and may be elevated in response to chemotherapy. The NK1 receptor is a G-protein receptor coupled to the inositol phosphate signal-transduction pathway and is found in both the nucleus tractus solitarii and the area postrema. (BOC Sciences Bioactive Compounds)
Compound Sets
14
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Enamine Bioactive Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
ReFrame library
ZINC Tool Compounds
External IDs
85
Properties
(calculated by RDKit )
Molecular Weight
616.26
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
2
cLogP
6.65
TPSA
47.1
Fraction CSP3
0.53
Chiral centers
3.0
Largest ring
6.0
QED
0.36
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
NK1 antagonist
Cytochrome P450
Neurokinin Receptor
Pathway
GPCR/G protein
Metabolic Enzyme/Protease
Neuronal Signaling
Source data